Histiocytosis
MONDO:0002637A morphologic finding indicating tissue infiltration by non-neoplastic or neoplastic histiocytes.
Also known as: histiocytic infiltrate, histiocytic syndrome, histiocytic and dendritic cell neoplasms
81 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
Targeted drug ivosidenib tested in kids with rare, returning cancers
Disease control OngoingThis phase 2 trial tested the drug ivosidenib in children and young adults (ages 1 to 21) with solid tumors, lymphomas, or histiocytic disorders that have an IDH1 mutation and have either come back after treatment or not responded. The goal was to see if the drug could shrink or …
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Experimental drug shows promise for rare immune disorder
Disease control OngoingThis study tests the drug clofarabine in 25 people with Langerhans cell histiocytosis (LCH) or related disorders that have returned or not improved with standard therapy. The goal is to see if clofarabine can shrink or eliminate disease. Participants receive the drug and are moni…
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New hope for kids with tough cancers: targeted drug shows promise in Gene-Matched tumors
Disease control OngoingThis study tests a drug called erdafitinib in children and young adults (ages 1 to 21) whose cancers have come back or are not responding to treatment and have specific changes in FGFR genes. The drug works by blocking enzymes that help cancer cells grow. The main goal is to see …
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for kids with rare cancers: targeted drug selpercatinib tested in phase 2 trial
Disease control OngoingThis phase 2 trial tests the drug selpercatinib in children and young adults (ages 1 to 21) with advanced cancers that have a specific genetic change called a RET alteration. The goal is to see if the drug can shrink tumors or stop them from growing. Only one participant has been…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Stem cell transplant offers new hope for kids with rare immune diseases
Disease control OngoingThis study tests a donor stem cell transplant for people with severe immune system problems, like SCID and Wiskott-Aldrich syndrome. The goal is to help the body make healthy blood cells and fight infections. Participants receive donated stem cells to rebuild their immune system.…
Phase: NA • Sponsor: Masonic Cancer Center, University of Minnesota • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for kids with tough cancers: targeted drug attacks gene flaw
Disease control OngoingThis study tests a drug called ulixertinib in children and teens whose advanced cancers have a specific genetic change in the MAPK pathway. The goal is to see if the drug can shrink or control the tumor. About 20 participants with various solid tumors, lymphomas, or related disor…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for kids with rare cancers: targeted drug larotrectinib tested in small trial
Disease control OngoingThis phase 2 trial is testing the drug larotrectinib in children and young adults (ages 1 to 21) with advanced solid tumors, non-Hodgkin lymphoma, or histiocytic disorders that have a specific genetic change called an NTRK fusion. The cancers have either come back after treatment…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Targeted drug shows promise for kids with Tough-to-Treat cancers
Disease control OngoingThis study tested the drug ensartinib in 13 children and young adults (ages 1–21) whose cancers had come back or did not respond to treatment and had specific ALK or ROS1 gene changes. The goal was to see if the drug could shrink or stop tumor growth. While the drug targets cance…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Precision drug tipifarnib targets rare HRAS cancers in kids
Disease control OngoingThis study tests a drug called tipifarnib in children and young adults (ages 1 to 21) whose cancers have a specific change in the HRAS gene. The cancers are advanced or have come back after treatment. The goal is to see if tipifarnib can shrink tumors or stop them from growing. A…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Gentler transplant shows promise for kids with blood diseases
Disease control OngoingThis study tests a milder chemotherapy and immune-suppressing regimen before a stem cell transplant for children and young adults with non-malignant blood disorders like sickle cell disease or immune deficiencies. The goal is to safely achieve donor cell engraftment with fewer si…
Phase: PHASE2 • Sponsor: Children's Hospital of Philadelphia • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New hope for kids with rare immune disorder: international trial tests drug cocktails
Disease control OngoingThis study tests several drug combinations and stem cell transplants in 1,400 children with Langerhans cell histiocytosis, a rare immune disease. The goal is to prevent the disease from coming back and reduce lasting problems like hormone deficiencies and brain issues. Researcher…
Phase: PHASE2, PHASE3 • Sponsor: North American Consortium for Histiocytosis • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Promising combo aims to tame relapsed childhood cancers
Disease control OngoingThis study tests a daily combination of sirolimus, celecoxib, and low-dose chemotherapy in 46 children whose solid or brain tumors have returned or not responded to standard treatment. The goal is to see if this approach can shrink tumors or stop them from growing. While not a cu…
Phase: PHASE2 • Sponsor: Emory University • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Old drug, new hope: lenalidomide tackles rare histiocyte cancers
Disease control OngoingThis phase 2 study tests the chemotherapy drug lenalidomide (Revlimid) in 12 adults with one of three rare histiocyte disorders: Langerhans cell histiocytosis, Erdheim-Chester disease, or histiocytic sarcoma. The goal is to see how many patients achieve disease control or remissi…
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New stem cell approach could fix immune systems in kids
Disease control OngoingThis Phase II trial tests a stem cell transplant from unrelated or partially matched family donors for children and young adults with severe immune deficiencies. The stem cells are specially processed to remove certain immune cells, aiming to reduce complications. The goal is to …
Phase: PHASE2 • Sponsor: Children's Hospital of Philadelphia • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New hope for rare cancer: drug cocktail targets stubborn LCH
Disease control OngoingThis phase 2 trial tests a combination of three drugs—selinexor, thalidomide, and dexamethasone—in 40 adults with relapsed or refractory Langerhans cell histiocytosis (LCH), a rare immune cell disorder. The goal is to see if the XTD regimen can shrink tumors and delay disease pro…
Phase: PHASE2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Newborn screening study aims to catch rare diseases at birth
Diagnosis OngoingThis study offers voluntary screening for newborns in North Carolina to detect a wide range of rare health conditions early. Using a small blood sample already collected at birth, the program tests for dozens of disorders, including spinal muscular atrophy, cystic fibrosis, and m…
Sponsor: RTI International • Aim: Diagnosis
Last updated Jul 03, 2026 00:00 UTC
-
New york program offers extra screening for 100,000 newborns
Diagnosis ENROLLING_BY_INVITATIONScreenPlus is a large pilot program that offers families the option to have their newborn screened for a panel of rare genetic disorders, in addition to standard newborn screening. The study aims to screen 100,000 infants born at eight hospitals in New York. Researchers will eval…
Sponsor: Albert Einstein College of Medicine • Aim: Diagnosis
Last updated Jun 26, 2026 16:15 UTC
-
Scientists hunt for genetic clues in rare blood disorders
Knowledge-focused TerminatedThis study looks at the genetic makeup of rare blood diseases like Castleman disease and Langerhans cell histiocytosis. Researchers will analyze blood or tissue samples from 135 participants to find genetic changes that could be targeted by existing or experimental therapies. The…
Phase: NA • Sponsor: Case Comprehensive Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Can DNA tests pick the right cancer drug for kids?
Knowledge-focused OngoingThis study screens children and teens with advanced solid tumors, lymphomas, or histiocytic disorders to find genetic changes in their cancer cells. Participants undergo biopsies and scans to identify mutations that can be targeted by specific drugs. The goal is to see if matchin…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Rare disease study probes hidden brain effects
Knowledge-focused OngoingThis study looks at how histiocytosis—a group of rare disorders—may affect memory, thinking, and brain structure. Researchers will test 13 adults with these conditions using thinking tasks and MRI scans. The goal is to better understand brain changes, not to provide treatment.…
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:31 UTC
-
Gene hunt: can DNA explain a rare childhood disease?
Knowledge-focused OngoingThis study investigates how inherited genetic variations, especially in the SMAD6 gene, influence a person's risk of developing Langerhans cell histiocytosis (LCH), a rare disease where immune cells build up in tissues. Researchers will collect saliva or cheek swabs from 647 chil…
Sponsor: Children's Oncology Group • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:09 UTC
-
Rare disease diagnosis boost: new study eyes key clues in ASMD patients
Knowledge-focused OngoingThis study looks at symptoms and lab tests to help doctors better diagnose acid sphingomyelinase deficiency (ASMD), also known as Niemann-Pick disease, a rare genetic disorder. Researchers will track changes in spleen and liver size using ultrasound over 12 months in 7 patients. …
Sponsor: Sohag University • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:03 UTC
-
Massive childhood cancer registry launches to unlock secrets of the disease
Knowledge-focused OngoingThis study is a large registry that collects information from children diagnosed with cancer across the US and Canada. Its goal is to help researchers understand patterns, causes, and characteristics of childhood cancer. No treatments or drugs are given—it is purely for research …
Sponsor: Children's Oncology Group • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:59 UTC
-
New disease found in drug users: researchers race to understand it
Knowledge-focused ENROLLING_BY_INVITATIONThis observational study looks at a newly identified lung condition called histiocytosis in people who inject drugs. Researchers will study 30 patients to understand symptoms, diagnosis, and outcomes. They will also test new ways to detect a substance called polyvinylpyrrolidone …
Sponsor: Tampere University Hospital • Aim: Knowledge-focused
Last updated Jun 26, 2026 16:26 UTC